LGALS3 and Parkinson disease: Our study does not support caspase inhibition as a therapeutic option for PD; however, pharmacological targeting of GAL3 appears to be a promising preclinical strategy to combat exacerbated deleterious microglial response towards the dopaminergic system in neurodegenerative conditions.